- Report
- April 2025
- 250 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 248 Pages
Global
From €4505EUR$4,950USD£3,862GBP
- Report
- March 2025
- 250 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- October 2022
- 204 Pages
Global
From €4505EUR$4,950USD£3,862GBP
- Report
- February 2025
- 197 Pages
India
From €2275EUR$2,500USD£1,951GBP
The Contract Research and Manufacturing Services (CRAMS) market within the Pharmaceutical Manufacturing industry is a rapidly growing sector. It involves the outsourcing of research and development (R&D) activities, as well as the manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). CRAMS providers offer a range of services, from pre-clinical and clinical trials to drug discovery and development, as well as the production of APIs and FDFs. This allows pharmaceutical companies to focus on their core competencies, while outsourcing the more complex and costly activities.
CRAMS providers are also able to offer cost-effective solutions, as they have access to the latest technologies and can leverage economies of scale. This allows them to provide high-quality services at competitive prices.
Some of the major companies in the CRAMS market include Lonza, Boehringer Ingelheim, Catalent, Jubilant Life Sciences, and Aurobindo Pharma. Show Less Read more